Valuation: Fortress Biotech, Inc.

Market Cap 97.05M 83.25M 77.74M 71.32M 134M 9.28B 136M 917M 359M 4.65B 364M 356M 15.38B P/E 2026 *
1.21x
P/E 2027 * -5.82x
Enterprise Value 97.05M 83.25M 77.74M 71.32M 134M 9.28B 136M 917M 359M 4.65B 364M 356M 15.38B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 0.79x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-2.92%
1 week+2.73%
Current month-9.74%
1 month-15.17%
3 months+11.66%
6 months-18.82%
Current year-22.81%
1 week 2.7
Extreme 2.7
3.06
1 month 2.57
Extreme 2.57
3.65
Current year 2.18
Extreme 2.18
4.53
1 year 1.99
Extreme 1.9907
4.53
3 years 1.24
Extreme 1.24
7.2
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 2013-12-19
Director of Finance/CFO 51 2012-02-21
Director of Finance/CFO 36 2022-08-15
Director TitleAgeSince
Director/Board Member 74 2008-11-30
Chairman 71 2013-12-19
Director/Board Member 63 2006-05-31
Date Insider Type Main position Quantity % Market Cap.
1/1/26 Free

Director

27,322 0.0880%
1/1/26 Free

Director

27,322 0.0880%
1/1/26 Free

Director

27,322 0.0880%
Change 5-day change 1-year change 3-year change Capi.($)
-2.92%+2.73%+29.00%-58.48% 97.05M
+3.73%+5.00%+46.54%-0.77% 80.91B
+5.49%+20.35%-38.64%-38.47% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-1.80%+13.14%+167.24% 47.97B
+2.95%+4.70%+57.48%-17.50% 31.41B
+146.32%+149.22%+468.54%+42.85% 25.14B
+3.32%+5.76%+49.46%+96.87% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+4.68%+66.64%+126.90% 16.93B
Average +16.72%+3.96%+68.63%+56.13% 35.27B
Weighted average by Cap. +13.24%+3.07%+51.27%+48.38%

Financials

2026 *2027 *
Net sales 79.88M 68.52M 63.98M 58.7M 110M 7.63B 112M 755M 296M 3.83B 300M 293M 12.66B 123M 106M 98.52M 90.39M 170M 11.76B 173M 1.16B 455M 5.9B 462M 452M 19.5B
Net income 90.51M 77.64M 72.5M 66.52M 125M 8.65B 127M 855M 335M 4.34B 340M 332M 14.35B -20.84M -17.87M -16.69M -15.31M -28.8M -1.99B -29.27M -197M -77.12M -999M -78.24M -76.54M -3.3B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
26-08-19 $2.835 -2.58% 300,076
26-08-18 $2.910 +3.19% 593,190
26-08-17 $2.820 -3.75% 838,776
26-08-14 $2.930 -1.68% 1,031,522
26-08-13 $2.980 +8.36% 1,394,128
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.910USD
Average target price
11.00USD
Spread / Average Target
+278.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock